Journal of the American Academy of Dermatology · 2019
Management of Kaposi sarcoma after solid organ transplantation: A European retrospective study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Delyon Julie, Rabate Clementine, Euvrard Sylvie, Harwood Catherine A, Proby Charlotte, Güleç A Tülin, Seçkin Deniz, Del Marmol Veronique, Bouwes-Bavinck Jan Nico, Ferrándiz-Pulido Carla, Ocampo Maria Andrea, Barete Stephane, Legendre Christophe, Francès Camille, Porcher Raphael, Lebbe Celeste, Skin Care in Organ Transplant Patients Europe (SCOPE) group
Аннотация
BACKGROUND: Systemic therapeutic management of post-transplant Kaposi sarcoma (KS) is mainly based on 3 axes: reduction of immunosuppression, conversion to mammalian target of rapamycin (mTOR) inhibitors, chemotherapy, or a combination of these.
OBJECTIVE: To obtain an overview of clinical strategies about the current treatment of KS.
METHODS: We conducted a multicenter retrospective cohort study including 145 solid organ transplant recipients diagnosed with KS between 1985 and 2011 to collect data regarding first-line treatment and response at 6 months.
RESULTS: Overall, 95%, 28%, and 16% of patients had reduction of immunosuppression, conversion to mTOR inhibitor, and chemotherapy, respectively. Patients treated with chemotherapy or mTOR inhibitor conversion were more likely to have visceral KS. At 6 months, 83% of patients had response, including 40% complete responses.
LIMITATIONS: The retrospective design of the study.
CONCLUSION: Currently available therapeutic options seem to be effective to control KS in most patients. Tapering down the immunosuppressive regimen remains the cornerstone of KS management.
OBJECTIVE: To obtain an overview of clinical strategies about the current treatment of KS.
METHODS: We conducted a multicenter retrospective cohort study including 145 solid organ transplant recipients diagnosed with KS between 1985 and 2011 to collect data regarding first-line treatment and response at 6 months.
RESULTS: Overall, 95%, 28%, and 16% of patients had reduction of immunosuppression, conversion to mTOR inhibitor, and chemotherapy, respectively. Patients treated with chemotherapy or mTOR inhibitor conversion were more likely to have visceral KS. At 6 months, 83% of patients had response, including 40% complete responses.
LIMITATIONS: The retrospective design of the study.
CONCLUSION: Currently available therapeutic options seem to be effective to control KS in most patients. Tapering down the immunosuppressive regimen remains the cornerstone of KS management.